Literature DB >> 9445407

Axonal transection in the lesions of multiple sclerosis.

B D Trapp1, J Peterson, R M Ransohoff, R Rudick, S Mörk, L Bö.   

Abstract

BACKGROUND: Multiple sclerosis is an inflammatory demyelinating disease of the central nervous system and is the most common cause of neurologic disability in young adults. Despite antiinflammatory or immunosuppressive therapy, most patients have progressive neurologic deterioration that may reflect axonal loss. We conducted pathological studies of brain tissues to define the changes in axons in patients with multiple sclerosis.
METHODS: Brain tissue was obtained at autopsy from 11 patients with multiple sclerosis and 4 subjects without brain disease. Fourteen active multiple-sclerosis lesions, 33 chronic active lesions, and samples of normal-appearing white matter were examined for demyelination, inflammation, and axonal pathologic changes by immunohistochemistry and confocal microscopy. Axonal transection, identified by the presence of terminal axonal ovoids, was detected in all 47 lesions and quantified in 18 lesions.
RESULTS: Transected axons were a consistent feature of the lesions of multiple sclerosis, and their frequency was related to the degree of inflammation within the lesion. The number of transected axons per cubic millimeter of tissue averaged 11,236 in active lesions, 3138 at the hypocellular edges of chronic active lesions, 875 in the hypocellular centers of chronic active lesions, and less than 1 in normal-appearing white matter from the control brains.
CONCLUSIONS: Transected axons are common in the lesions of multiple sclerosis, and axonal transection may be the pathologic correlate of the irreversible neurologic impairment in this disease.

Entities:  

Mesh:

Year:  1998        PMID: 9445407     DOI: 10.1056/NEJM199801293380502

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  976 in total

1.  Quantitative assessment of neurologic deficits in a chronic progressive murine model of CNS demyelination.

Authors:  D B McGavern; L Zoecklein; K M Drescher; M Rodriguez
Journal:  Exp Neurol       Date:  1999-07       Impact factor: 5.330

Review 2.  The role of TNFalpha and lymphotoxin in demyelinating disease.

Authors:  C Lock; J Oksenberg; L Steinman
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

3.  Diffusion-weighted MR imaging of multiple sclerosis: added clinical value or "just another pretty face?".

Authors:  M H Lev
Journal:  AJNR Am J Neuroradiol       Date:  2000-05       Impact factor: 3.825

4.  Axonal loss results in spinal cord atrophy, electrophysiological abnormalities and neurological deficits following demyelination in a chronic inflammatory model of multiple sclerosis.

Authors:  D B McGavern; P D Murray; C Rivera-Quiñones; J D Schmelzer; P A Low; M Rodriguez
Journal:  Brain       Date:  2000-03       Impact factor: 13.501

5.  Drug treatment of multiple sclerosis

Authors: 
Journal:  West J Med       Date:  2000-12

6.  Effect of midthoracic spinal cord constriction on catalytic nitric oxide synthase activity in the white matter columns of rabbit.

Authors:  N Lukácová; D Cízková; M Marsala; J Pavel; P Jalc; I Sulla; J Kafka; J Marsala
Journal:  Neurochem Res       Date:  2000-08       Impact factor: 3.996

7.  Acute multiple sclerosis characterized by extensive mononuclear phagocyte infiltration.

Authors:  D C Shields; N G Avgeropoulos; N L Banik; W R Tyor
Journal:  Neurochem Res       Date:  2000-11       Impact factor: 3.996

Review 8.  Drug treatment of multiple sclerosis.

Authors:  C H Polman; B M Uitdehaag
Journal:  BMJ       Date:  2000 Aug 19-26

Review 9.  Maintenance and loss of self-tolerance in B cells.

Authors:  A Iglesias
Journal:  Springer Semin Immunopathol       Date:  2001-12

10.  Quantitative functional MR imaging of the visual cortex at 1.5 T as a function of luminance contrast in healthy volunteers and patients with multiple sclerosis.

Authors:  Scott H Faro; Feroze B Mohamed; Joseph I Tracy; Robert M Elfont; Alexander B Pinus; Fred D Lublin; Robert A Koenigsberg; Cheng Y Chen; Fong Y Tsai
Journal:  AJNR Am J Neuroradiol       Date:  2002-01       Impact factor: 3.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.